<DOC>
	<DOCNO>NCT02278055</DOCNO>
	<brief_summary>The purpose study find Radium-223 effective reduce cancer pain within 12 week treatment . In order see Radium-223 effective , patient 's level pain follow throughout study .</brief_summary>
	<brief_title>Non-Randomized Trial Assessing Pain Efficacy With Radium-223 Symptomatic Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Males age 18 year age Histological cytological proof prostate adenocarcinoma Castrate serum testosterone level : ≤50 ng/dL ( ≤1.7 nmol/L ) Patients experienced disease progression despite initial hormonal therapy , either orchiectomy use GnRH agonist combination antiandrogen , must first progress anti androgen withdrawal prior eligible . The minimum time frame document failure antiandrogen withdrawal four week . Patients secondline ( beyond ) hormonal maneuver , patient PSA decline combine androgen blockade first line therapy , need progress AAW order eligible . Known progressive castrationresistant disease , define : Serum PSA progression define two consecutive increase PSA previous reference value within 6 month first treatment , measurement least one week apart . Serum PSA screen ≥ 2 ng/mL Documented appearance new lesion bone scintigraphy ECOG Performance Status 02 2 bone metastasis demonstrate bone scintigraphy Pain baseline measure BPI bad pain score average ≥ 3 . The BPI bad pain score average base bad pain score complete patient 7 consecutive pretreatment day . A minimum 4 day pain score must complete patient 7 day window order calculate average worst pain score . The investigator optimize subject 's pain regimen prior study entry . Normal organ function acceptable initial laboratory value : WBC ≥ 3 x 109 /L ANC ≥ 1.5 x 109 /L Platelets ≥ 100 x 109 /L Hemoglobin ≥ 9.0 g/dL Creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) Bilirubin ≤ 1.5 x ULN AST/ALT ≤ 2.5 x ULN Albumin &gt; 25 g/L All acute toxicity result prior treatment must resolve NCICTCAE v4.0 Grade 1 less time signing Informed Consent Form ( ICF ) [ Note : Ongoing grade 2 neuropathy result treatment cytotoxic chemotherapy regimen permit ] Life expectancy least 6 month Willing able provide write informed consent HIPAA authorization release personal health information NOTE : HIPAA authorization may either include informed consent obtain separately Willing able comply protocol , include followup visit , examination well ability selfreport pain fatigue use Patient Reported Outcome ( PRO ) instrument Willingness use adequate method contraception begin sign ICF least 30 day last dose study drug Prior exposure Radium223 Received investigational therapy within 4 week prior registration schedule receive one treatment period Received new anticancer agent within 4 week prior registration Received external beam radiotherapy within 4 week prior registration Received systemic therapy radionuclides ( e.g . strontium89 , samarium153 , rhenium186 rhenium188 ) treatment bone metastases Treatment cytotoxic chemotherapy within 4 week prior registration Symptomatic nodal disease , i.e . scrotal , penile leg edema . Visceral metastasis ( include cerebral metastasis ) CRPC ( &gt; 2 lung and/or liver metastases [ size ≥2cm ] ; Lymphadenopathy exceed 6 cm shortaxis diameter size pelvic lymphadenopathy thought contributor concurrent hydronephrosis ) , assess CT , MRI chest Xray within 8 week prior registration . Concurrent chemotherapy . Patients may nonchemotherapy anticancer treatment , per FDA label Radium223 , provide change primary pain assessment period Major surgery within 30 day prior registration . Imminent spinal cord compression base clinical finding and/or magnetic resonance imaging ( MRI ) . Treatment complete spinal cord compression . Patients , `` currently active , '' second malignancy nonmelanoma skin cancer noninvasive bladder cancer insitu noninvasive malignancy . Patients complete therapy prior malignancy free disease ≥3 year eligible . Any serious illness medical condition , limited : Any infection ≥ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 Grade 2 Cardiac failure New York Heart Association ( NYHA ) III IV Crohn 's disease ulcerative colitis Bone marrow dysplasia Fecal incontinence Any condition , opinion Investigator , would make subject unsuitable trial participation NOTE : Any patient find ineligible prior treatment initiation require rescreening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Radium-223</keyword>
	<keyword>14-098</keyword>
	<keyword>Prostate Cancer Clinical Trials Consortium</keyword>
</DOC>